In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.

Company Name	Title of Study	Update Date
Janssen, Jahnson & Johnson	Multicenter observational drug registry of Opsumit® (macitentan) in connective tissue disease associated pulmonary arterial hypertension (CTD-PAH) in real world Taiwan clinical setting	2023-10-03
Bayer Taiwan Co., Ltd	Systemic treatment patterns of hepatocellular carcinoma (HCC) in Taiwan	2023-08-24
Bayer Taiwan Co., Ltd	Copanlisib in Indolent Non-Hodgkin Lymphoma Patients: A Real-world Taiwan Observation Multicenter Study	2023-08-24
Bayer Taiwan Co., Ltd	Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients / DAROL	2023-06-20
GSK	A Phase IV, Prospective, Non-Interventional Cohort Study of Fostemsavir Based Regimen In Heavily Treatment Experienced Patient With Hiv-1 Infection In Taiwan	2023-05-24
AbbVie Biopharmaceuticals GmbH	Prospective Observational Cohort study of patients with moderate to severe chronic plaque psoriasis in Taiwan	2023-03-24
Gilead Sciences Hong Kong Ltd. Taiwan Branch	A Post-Authorization Study to Evaluate Safety and Clinical Outcomes in COVID-19 Patients Treated with Veklury® (Remdesivir) in Taiwan	2023-01-06
Gilead Sciences Hong Kong Limited, Taiwan Branch	Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Asia.	2023-01-06
Bayer Taiwan Co., Ltd.	Observational study evaluating the physical activity in a subset of damoctocog alfa pegol treated Hemophilia A patients who are enrolled in the HEM-POWR study.	2022-11-29
Bayer Taiwan Co., Ltd.	Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A	2022-07-28